Low maternal serum alpha-fetoprotein and perinatal outcome

Area of Science:

• Prenatal diagnostics
• Maternal serum screening

Background:

• Maternal serum alpha-fetoprotein (MSAFP) screening is a key component of prenatal diagnostics.
• Low MSAFP values have historically been associated with adverse pregnancy outcomes, prompting further investigation.

Purpose of the Study:

• To prospectively evaluate pregnancy outcomes in women with low maternal serum alpha-fetoprotein (MSAFP) values (<0.4 multiples of the median).
• To determine if low MSAFP levels correlate with increased fetal loss or pregnancy complications.

Main Methods:

• Prospective follow-up of pregnancy outcomes in 1531 women screened for MSAFP.
• Analysis of pregnancies with MSAFP values <0.4 multiples of the median, with a subgroup analysis for values <0.25 multiples of the median.
• Comparison of outcomes between women with low MSAFP and those with normal MSAFP values (0.4-2.49 multiples of the median).

Main Results:

• All three cases of autosomal trisomy were detected via amniocentesis in the screened population.
• Fetal losses were less frequent in women with low MSAFP (<0.4 MoM) compared to previous reports.
• No significant differences were observed in antepartum/intrapartum complications, birth weight, gestational age, cord pH, or Apgar scores between low MSAFP and normal MSAFP groups.

Conclusions:

• Low maternal serum alpha-fetoprotein values in viable pregnancies are associated with a more favorable prognosis than previously suggested.
• MSAFP screening, even with potential assay limitations, can aid in detecting chromosomal abnormalities.
• Current data indicate that low MSAFP levels alone do not predict adverse pregnancy outcomes or complications.